Regeneron Pharmaceuticals Inc.
NASDAQ · REGN·Tarrytown, NY·Pharma·Approved
Integrated biopharmaceutical company anchored by blockbuster Dupixent (IL-4/13) and Eylea (anti-VEGF) franchises. Regeneron's VelociSuite antibody discovery platform supports a deep pipeline spanning oncology (Libtayo, bispecifics), hematology, and genetic medicines.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Regeneron Investor Presentation | Corporate overview | January 1, 2026 | 36 |